Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.87)
# 1,571
Out of 4,789 analysts
80
Total ratings
45.76%
Success rate
7.46%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Initiates: Hold | $22 | $16.61 | +32.45% | 16 | Feb 11, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $10.09 | +48.66% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $3.54 | +125.99% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $17.09 | +192.57% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $110.60 | +22.97% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $2.86 | +459.44% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $12.38 | +401.01% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $1.23 | +875.61% | 6 | Dec 12, 2023 | |
| SAGE Sage Therapeutics | Initiates: Hold | $21 | $7.95 | +164.15% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $63.82 | +70.79% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.10 | +627.27% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.36 | +635.29% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $5 | $0.35 | +1,316.03% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $2.81 | +113.90% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $2.51 | +736.65% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $76.29 | -69.85% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $18.59 | +93.65% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
Feb 11, 2025
Initiates: Hold
Price Target: $22
Current: $16.61
Upside: +32.45%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $10.09
Upside: +48.66%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $3.54
Upside: +125.99%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $17.09
Upside: +192.57%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $110.60
Upside: +22.97%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $2.86
Upside: +459.44%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $12.38
Upside: +401.01%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $1.23
Upside: +875.61%
Sage Therapeutics
Dec 12, 2023
Initiates: Hold
Price Target: $21
Current: $7.95
Upside: +164.15%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $63.82
Upside: +70.79%
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $1.10
Upside: +627.27%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $1.36
Upside: +635.29%
Nov 11, 2022
Maintains: Buy
Price Target: $7 → $5
Current: $0.35
Upside: +1,316.03%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $2.81
Upside: +113.90%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $2.51
Upside: +736.65%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $76.29
Upside: -69.85%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $18.59
Upside: +93.65%